Obesity-associated hepatic steatosis and dyslipidemia were also significantly reversed in Zucker (fa/fa) rats after 8 weeks of treatment with CB1 specific antagonist, suggesting a direct peripheral effect on carbohydrate and lipid metabolism after blocking CB1 in the liver. This evidence concerns the gene CNR1 and metabolic syndrome.